Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Barratt-Redrow merger one step closer to regulatory approval

(Sharecast News) - The competition authority has announced that the allowances made by Barratt Developments and Redrow in order to pave way for regulatory approval may just be enough to get the green light. The initial phase of a Competition and Markets Authority investigation revealed issues in one of the 400 local areas where the two companies overlap, prompting the housebuilders to agree on "suitable undertaking" to address these concerns.

The CMA said on Wednesday it "considers that there are reasonable grounds for believing that the undertakings offered by the parties or a modified version of them, might be accepted by the CMA under the Enterprise Act 2002."

The regulator has until 18 October to decided whether or not to accept the undertakings. If accepted, it would avoid the need for a full Phase 2 investigation.

Despite this outstanding issue, the merger is due to go ahead this week, with Redrow's stock set to be deleted from the FTSE 250 at the end of Wednesday's trading session.

The companies announced on Monday that they would waive the CMA condition on their impending transaction and push ahead with the tie-up, though the CMA has the authority to prevent the full integration of the businesses until their proposed undertakings have been formally agreed.

Share this article

Related Sharecast Articles

PepsiCo cuts revenue outlook again
(Sharecast News) - PepsiCo cut its annual organic revenue guidance again on Tuesday as it highlighted a "subdued" performance in North America in the third quarter.
Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.